ARTICLE | Clinical News
Titan begins Phase II
April 10, 2001 7:00 AM UTC
TTP began a Phase II study of a combination of its CeaVac and TriAb monoclonal antibodies to treat non-small cell lung cancer (NSCLC). The study will assess the safety and preliminary efficacy of the ...